JS‑K induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways

  • Authors:
    • Zeqing Song
    • Yongxin Yin
    • Siyuan Hao
    • Jianmao Wei
    • Bin Liu
    • Xiaojie Huang
    • Chenfeng Gao
    • Runzhi Zhu
    • Weiguo Liao
    • De Cai
  • View Affiliations

  • Published online on: April 9, 2019     https://doi.org/10.3892/or.2019.7104
  • Pages: 3475-3487
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is one of the most common malignancies worldwide, with high mortality and morbidity rates. O2‑​(2,4‑​dinitrophenyl)‑1‑​[(4‑ethoxycarbonyl)piperazin‑1‑yl]diazen‑1‑ium‑1,2‑diolate (JS‑K) is a potent anticancer agent that acts against a subset of human non‑small cell lung cancer (NSCLC) cell lines; however, the underlying mechanisms of JS‑K in NSCLC remain unclear. The present study aimed to evaluate the anticancer effect of JS‑K and investigate its underlying mechanisms in A549 and H460 cells. In the present study, A549 and H460 cells were treated with JS‑K, and then evaluated by cell viability assay, flow cytometry and western blot analysis. JS‑K markedly induced cell cycle arrest at the G2/M phase in a concentration and time‑dependent manner in both cell lines. This was associated with increased expression levels of p53, and the cell cycle inhibitors p21WAF1/CIP1 and p27KIP1, which, in turn, inhibited the expression of Cdc2, cyclin B1 and cyclin‑dependent kinase 2. In addition, JS‑K‑induced inhibition of proliferation was revealed to be partially modulated by the upregulation of p53 and p21WAF1, the ratio of Bax/Bcl‑2, and the activation of both the intrinsic and extrinsic apoptotic pathways in A549 and H460 cells. These results demonstrated that JS‑K could trigger cell cycle arrest at the G2/M phase and apoptosis in A549 and H460 cells, which was likely mediated via the p53/p21WAF1/CIP1 and p27KIP1 pathways. Overall, the results indicated that JS‑K may be used as an anticancer agent for the treatment of NSCLC.

References

1 

Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Daniels MG, Bowman RV, Yang IA, Govindan R and Fong KM: An emerging place for lung cancer genomics in 2013. J Thorac Dis. 5 (Suppl 5):S491–S497. 2013.PubMed/NCBI

3 

Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J and Bischof M: Long-term survival of cancer patients compared to heart failure and stroke: A systematic review. BMC Cancer. 10:1052010. View Article : Google Scholar : PubMed/NCBI

5 

Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X and Soukiasian HJ: Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther. 18:359–368. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 4 (Suppl 5):S389–S396. 2013.

7 

Farhat FS and Houhou W: Targeted therapies in non-small cell lung carcinoma: What have we achieved so far? Ther Adv Med Oncol. 5:249–270. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Pirozynski M: 100 years of lung cancer. Respir Med. 100:2073–2084. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Schwartz AG, Prysak GM, Bock CH and Cote ML: The molecular epidemiology of lung cancer. Carcinogenesis. 28:507–518. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Spiro SG and Silvestri GA: One hundred years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Boil. 7:1700702017. View Article : Google Scholar

12 

Vilmar AC and Sorensen JB: Customising chemotherapy in advanced nonsmall cell lung cancer: Daily practice and perspectives. Eur Respir Rev. 20:45–52. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Wang T, Nelson RA, Bogardus A and Grannis FW Jr: Five-year lung cancer survival: Which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Zhang H, Feng QQ, Gong JH and Ma JP: Anticancer effects of isofraxidin against A549 human lung cancer cells via the EGFR signaling pathway. Mol Med Rep. 18:407–414. 2018.PubMed/NCBI

15 

Bailey SM, Meyne J, Chen DJ, Kurimasa A, Li GC, Lehnert BE and Goodwin EH: DNA double-strand break repair proteins are required to cap the ends of mammalian chromosomes. Proc Natl Acad Sci USA. 96:14899–14904. 1999. View Article : Google Scholar : PubMed/NCBI

16 

Vazquez A, Bond EE, Levine AJ and Bond GL: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 7:979–987. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Choisy-Rossi C, Reisdorf P and Yonish-Rouach E: Mechanisms of p53-induced apoptosis: In search of genes which are regulated during p53-mediated cell death. Toxicol Lett. 102-103:491–496. 1998. View Article : Google Scholar : PubMed/NCBI

18 

Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI

19 

Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI

20 

Pietenpol JA and Stewart ZA: Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis. Toxicology. 181-182:475–481. 2002. View Article : Google Scholar : PubMed/NCBI

21 

Pflaum J, Schlosser S and Muller M: p53 family and cellular stress responses in cancer. Front Oncol. 4:2852014. View Article : Google Scholar : PubMed/NCBI

22 

Shi Y: Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 9:459–470. 2002. View Article : Google Scholar : PubMed/NCBI

23 

Yunlan L, Juan Z and Qingshan L: Antitumor activity of di-n- butyl-(2,6-difluorobenzohydroxamato)tin(IV) against human gastric carcinoma SGC-7901 cells via G2/M cell cycle arrest and cell apoptosis. PLoS One. 9:e907932014. View Article : Google Scholar : PubMed/NCBI

24 

Huang Z, Fu J and Zhang Y: Nitric oxide donor-based cancer therapy: Advances and prospects. J Med Chem. 60:7617–7635. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, Schrader M and Cronauer MV: JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells. BMC Cancer. 12:1302012. View Article : Google Scholar : PubMed/NCBI

26 

Liu L, Huang Z, Chen J, Wang J and Wang S: Protein phosphatase 2A mediates JS-K-induced apoptosis by affecting Bcl-2 family proteins in human hepatocellular carcinoma HepG2 cells. J Cell Biochem. 119:6633–6643. 2018. View Article : Google Scholar : PubMed/NCBI

27 

Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, et al: JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther. 2:409–417. 2003.PubMed/NCBI

28 

Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, et al: JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood. 110:709–718. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Qiu M, Chen L, Tan G, Ke L, Zhang S, Chen H and Liu J: A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells. Sci Rep. 5:151042015. View Article : Google Scholar : PubMed/NCBI

30 

Qiu M, Ke L, Zhang S, Zeng X, Fang Z and Liu J: JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo- sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin. Cancer Chemother Pharmacol. 80:275–286. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM and Tari AM: TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res. 10:R442008. View Article : Google Scholar : PubMed/NCBI

32 

Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM and Keefer LK: The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: Involvement of reactive oxygen species. J Pharmacol Exp Ther. 336:313–320. 2011. View Article : Google Scholar : PubMed/NCBI

33 

Ou X, Lu Y, Liao L, Li D, Liu L, Liu H and Xu H: Nitidine chloride induces apoptosis in human hepatocellular carcinoma cells through a pathway involving p53, p21, Bax and Bcl-2. Oncol Rep. 33:1264–1274. 2015. View Article : Google Scholar : PubMed/NCBI

34 

Shin SY, Yong Y, Kim CG, Lee YH and Lim Y: Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in HeLa cells. Cancer Lett. 287:231–239. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Hwang HJ, Kang YJ, Hossain MA, Kim DH, Jang JY, Lee SH, Yoon JH, Moon HR, Kim HS, Chung HY, et al: Novel dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivative, MHY-449, induces apoptosis and cell cycle arrest in HCT116 human colon cancer cells. Int J Oncol. 41:2057–2064. 2012. View Article : Google Scholar : PubMed/NCBI

36 

Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE, et al: Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 61:647–653. 2001.PubMed/NCBI

37 

Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E and Fornace AJ Jr: Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 411:102–107. 2001. View Article : Google Scholar : PubMed/NCBI

38 

Chen YL, Lin SZ, Chang JY, Cheng YL, Tsai NM, Chen SP, Chang WL and Harn HJ: In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochem Pharmacol. 72:308–319. 2006. View Article : Google Scholar : PubMed/NCBI

39 

Lew DJ and Kornbluth S: Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol. 8:795–804. 1996. View Article : Google Scholar : PubMed/NCBI

40 

Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI

41 

Srivastava RK, Chen Q, Siddiqui I, Sarva K and Shankar S: Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle. 6:2953–2961. 2007. View Article : Google Scholar : PubMed/NCBI

42 

Migita T, Oda Y, Naito S and Tsuneyoshi M: Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 94:973–979. 2002. View Article : Google Scholar : PubMed/NCBI

43 

O'Connell MJ, Walworth NC and Carr AM: The G2-phase DNA-damage checkpoint. Trends Cell Biol. 10:296–303. 2000. View Article : Google Scholar : PubMed/NCBI

44 

Chaudhary P, Sharma R, Sahu M, Vishwanatha JK, Awasthi S and Awasthi YC: 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway. J Biol Chem. 288:20532–20546. 2013. View Article : Google Scholar : PubMed/NCBI

45 

Guicciardi ME, Malhi H, Mott JL and Gores GJ: Apoptosis and necrosis in the liver. Compr Physiol. 3:977–1010. 2013.PubMed/NCBI

46 

Zhu X, Wang K, Zhang K, Zhang T, Yin Y and Xu F: Ziyuglycoside I inhibits the proliferation of MDA-MB-231 breast carcinoma cells through inducing p53-mediated G2/M cell cycle arrest and intrinsic/extrinsic apoptosis. Int J Mol Sci. 17:E19032016. View Article : Google Scholar : PubMed/NCBI

47 

McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 5:a0086562013. View Article : Google Scholar : PubMed/NCBI

48 

Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK: Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI

49 

Zhang Q, Ma S, Liu B, Liu J, Zhu R and Li M: Chrysin induces cell apoptosis via activation of the p53/Bcl-2/caspase-9 pathway in hepatocellular carcinoma cells. Exp Ther Med. 12:469–474. 2016. View Article : Google Scholar : PubMed/NCBI

50 

Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, et al: Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI

51 

Burmakin M, Shi Y, Hedstrom E, Kogner P and Selivanova G: Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI

52 

Zeng G, Liu J, Chen H, Liu B, Zhang Q, Li M and Zhu R: Dihydromyricetin induces cell cycle arrest and apoptosis in melanoma SK-MEL-28 cells. Oncol Rep. 31:2713–2719. 2014. View Article : Google Scholar : PubMed/NCBI

53 

Reed JC: Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34 (4 Suppl 5). S9–S19. 1997.

54 

Pettersson F, Dalgleish AG, Bissonnette RP and Colston KW: Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer. 87:555–561. 2002. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Song, Z., Yin, Y., Hao, S., Wei, J., Liu, B., Huang, X. ... Cai, D. (2019). JS‑K induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways . Oncology Reports, 41, 3475-3487. https://doi.org/10.3892/or.2019.7104
MLA
Song, Z., Yin, Y., Hao, S., Wei, J., Liu, B., Huang, X., Gao, C., Zhu, R., Liao, W., Cai, D."JS‑K induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways ". Oncology Reports 41.6 (2019): 3475-3487.
Chicago
Song, Z., Yin, Y., Hao, S., Wei, J., Liu, B., Huang, X., Gao, C., Zhu, R., Liao, W., Cai, D."JS‑K induces G2/M phase cell cycle arrest and apoptosis in A549 and H460 cells via the p53/p21WAF1/CIP1 and p27KIP1 pathways ". Oncology Reports 41, no. 6 (2019): 3475-3487. https://doi.org/10.3892/or.2019.7104